Soon-Shiong companies green-lighted to move cancer vaccine into clinic

Nantcell and Nantkwest Inc. have gained FDA permission to start enrolling a phase Ib/II trial of the Nant cancer vaccine, a step toward what Nantkwest CEO Patrick Soon-Shiong has said is a quest to develop a vaccine intended to induce immunogenic cell death and orchestrate patients' innate and adaptive immune systems.